Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models.

The Journal of clinical investigation - 16 Feb 2026

Xu Rongzhong, Wang Dongsheng, Ma Guangzhi, Yuan Xun, Chu Qian, Fan Songqing, Zhang Rener, Du Pan, Jia Shidong, Leal Ticiana A, Ramalingam Suresh S, Chen Zhen, Sun Shi-Yong

Abstract excerpt

The approval of sotorasib and adagrasib as the first KRAS G12C inhibitors has made the RAS oncogene a druggable target. However, they have modest objective response rates and short response durations. Therefore, strategies for improving RAS-targeted cancer therapy are urgently needed. Here, we found that both sotorasib and adagrasib promoted topoisomerase IIα (Topo IIα) proteasomal degradation in KRAS G12C-mutant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to DNA Topoisomerases, Type II

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Etoposide

Share to Piperazines

Share to Poly-ADP-Ribose Binding Proteins

Share to Pyridines

Share to Sulfonamides

Share to Topoisomerase II Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 41697749
DOI: 10.1172/JCI197192
PMCID: PMC12904700

Genes

KRAS
TOP2A

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models.PMID 41697749Read ↗

Differential Response and Resistance to KRAS-Targeted Therapy.Semantic proximity Read ↗

WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance.Semantic proximity Read ↗

Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugsSemantic proximity Read ↗

Targeting KRASG12C in colorectal cancer: the beginning of a new era.Semantic proximity Read ↗

Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive ReviewSemantic proximity Read ↗

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.Semantic proximity Read ↗

Cracking the Code: Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive ReviewSemantic proximity Read ↗

Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.Semantic proximity Read ↗

SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma.Semantic proximity Read ↗

Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer TherapySemantic proximity Read ↗

The Influence of Oncogenic RAS on Chemotherapy and Radiotherapy Resistance Through DNA Repair PathwaysSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.